Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178

International Journal of Cancer

Volumn 105, Issue 2, 2003, Pages 210-216

  Bettinotti, Maria P ^a   Panelli, Monica C ^a   Ruppe, Erin ^a   Mocellin, Simone ^a   Phan, Giao Q ^b   White, Donald E ^b   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immune response; Immunotherapy; MAGE; Melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; FREUND ADJUVANT; GAMMA INTERFERON; HLA ANTIGEN; HLA CW 0702; MAGE A12 PEPTIDE; PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; MALE; MELANOMA; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIZATION; VACCINATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; CASE-CONTROL STUDIES; CELLS, CULTURED; DNA PRIMERS; FEMALE; HLA-C ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNOTHERAPY; INTERFERON TYPE II; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 0037431558     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11045     Document Type: Article

References (28)

1. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp, CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 [see comments]. JAMA 1994;371:907-13.
2. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL. Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-66.
3. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997;18:175-82.
4. Coulie PG, van den Eynde BJ, van der Bruggen P, Van Pel A, Boon T. Antigens recognized by T-lymphocytes on human tumours. Biochem Soc Trans 1997;35:544-8.
5. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-62.
6. Rosenberg SA, Yang JC, Schwartzentruber D, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dufour E, Schwartzberg L, Spiess P, Wunderlich J, Parkhurst MR, et al. Immunologic and therapeutic evaluation of a synthetic tumor-associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 98;4:321-27.
7. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A [see comments]. Cancer J Sci Am 1997;3:37-44.
8. Lee K-H, Wang E, Nielsen M-B, Wunderlich J, Migueles.S., Connors M, Steinberg SM, Rosenberg SA, Marincola FM. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999;163:6292-300.
9. Lee K-H, Panelli MC, Kim CJ, Riker A, Roden M, Fetsch PA, Abati A, Bettinotti MP, Rosenberg SA, Marincola FM. Functional dissociation between local and systemic immune response following peptide vaccination. J Immunol 1998;161:4183-94.
10. Panelli MC, Bettinotti MP, Lally K, Li Y, Ohnmacht GA, Robbins PA, Riker A, Rosenberg SA, Marincola FM. Identification of a tumor infiltrating lymphocyte recognizing MAGE-12 in a melanoma metastasis with decreased expression of melanoma differentiation antigens. J Immunol 2000;164:4382-4392.
11. DePlaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Lurquin C, Brasseur R, Chomez P, et al. Structure, chromosomal localization and expression of 12 genes of the MAGE family. Immunogenetics 1994;40:360-369.
12. Marincola FM, Jaffe EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
13. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genomewide demethylafion. Proc Natl Acad Sci USA 1996;93:7149-7153.
14. Takahashi K, Shichijo S, Noguchi M, Hirohata M, Itoh K. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res 1995;55:3478-82.
15. Tomita Y, Nishiyama T, Fujiwara M, Sato S. Immunohistochemical detection of major histocompatibility complex antigens and quantitative analysis of tumour-infiltrating mononuclear cells in renal cell cancer. Br J Cancer 1990;62:354-9.
16. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-230.
17. Player MA, Barracchini KC, Simonis TB, Rivoltini L, Arienti F, Castelli C, Mazzocchi A, Belli F, Marincola FM. Differences in frequency distribution of HLA-A2 sub-types between American and Italian Caucasian melanoma patients: relevance for epitope specific vaccination protocols. J Immunother 1996;19:357-63.
18. Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch PA, Riker A, Kammula US, Rosenberg SA, Marincola FM. Short term kinetics of tumor antigen expression in response to vaccination. J Immunol 2001;167:1809-20.
19. Kammula US, Lee K-H, Riker A, Wang E, Ohnmacht GA, Rosenberg SA, Marincola, FM. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 1999;163:6867-79.
20. Kammula US, Marincola FM, Rosenberg SA. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst 2000;92:1336-44.
21. Marincola FM, Shamamian P, Rivoltini L, Salgaller ML, Reid J, Restifo NP, Simonis TB, Venzon D, White DE, Parkinson DR. HLA associations in the anti-tumor response against malignant melanoma. J Immunother 1996;18:242-52.
22. Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steinberg SM, Rosenberg SA, Marincola FM. Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998;75:517-24.
23. Zemmour J, Parham P. Distinctive polymorphism at the HLA-C locus: implications for the expression of HLA-C. J Exp Med 1992;176:937-50.
24. Coulie PG, Karanikas V, Colau D, Lurquin C, Laundry C, Marchand M, Dorval T, Brichard V, Boon T. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 2001;98:10290-5.
25. Heidecker L, Brasseur F, Probst-Kepper M, Gueguen M, Boon T, Van den Eynde B. Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12. J Immunol 2000;164:6041-5.
26. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996;56:4749-57.
27. Monsurro' V, Nielsen M-B, Perez-Diez A, Dudley ME, Wang E, Rosenberg SA, Marincola FM. Kinetics of TCR use in response to repeated epitope-specific immunization. J Immunol 2001;166:5817-25.
28. Wang E, Marincola FM. A natural history of melanoma: serial gene expression analysis. Immunol Today 2000;31:619-23.